Superiority of amino-modified chiral mesoporous silica nanoparticles in delivering indometacin

Figures & data

Figure 1. Installation diagram of in vitro drug intestinal permeability.

Table 1. Characteristic description of CMSN and Amino-CMSN.

			Surface area and pore volume analysis
			Sample	TEM	XRD	SBET	Vt
CMSN [20]	Nanoparticles with helical channels	A wide peak between 15° and 30° 2θ				525.36	0.45
Amino-CMSN [21]	Nanoparticles with denser helical channels	A wide peak between 15° and 30° 2θ	190.74	0.3923

Figure 2. In vitro release profiles of IMC, IMC-loaded CMSN and IMC-loaded Amino-CMSN.

Figure 3. Schematic diagram of transport route of orally administered MSN.

Figure 4. In vitro cumulative drug permeation quantity of IMC, IMC-loaded CMSN and IMC-loaded Amino-CMSN.

Figure 5. Haemolysis ratio of CMSN and Amino-CMSN.

Figure 6. BSA adsorption (%) of CMSN and Amino-CMSN.

Figure 7. Plasma drug concentration profiles of IMC, IMC-loaded CMSN and IMC-loaded Amino-CMSN.

Table 2 Pharmacokinetic parameters of IMC after oral administration of aqueous suspension of IMC, IMC-loaded CMSN and IMC-loaded Amino-CMSN.

Pharmacokinetic parameter	IMC	IMC-loaded CMSN	IMC-loaded Amino-CMSN
Cmax (μg/L)	34.274 ± 3.773	64.346 ± 32.586	75.939 ± 21.450
Tmax (h)	5.333 ± 1.155	4.333 ± 3.215	6.000 ± 0.000
AUC0→t (μg h/L)	491.021 ± 27.028	801.518 ± 98.188	958.830 ± 116.619
MRT (h)	10.430 ± 0.964	10.742 ± 3.639	11.811 ± 1.654

Each value represents the mean ± SD (n = 3).

Figure 8. Efficacy–time curve of anti-inflammatory activity of normal saline, IMC, IMC-loaded CMSN and IMC-loaded Amino-CMSN.

Figure 9. Histological examination for mucosal damage of rats following oral administration of (A) normal saline; (B) IMC; (C) IMC-loaded CMSN; (D) IMC-loaded amino-CMSN.